{"id":"NCT00165698","sponsor":"Eisai Co., Ltd.","briefTitle":"Efficacy and Safety Study on Menatetrenone in the Treatment of Postmenopausal Osteoporosis Women","officialTitle":"Efficacy and Safety Study on Menatetrenone in the Treatment of Postmenopausal Osteoporosis Women","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2005-05","primaryCompletion":"2007-01","completion":"2007-07","firstPosted":"2005-09-14","resultsPosted":"2011-08-11","lastUpdate":"2014-07-22"},"enrollment":240,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Postmenopausal Osteoporosis"],"interventions":[{"type":"DRUG","name":"menatetranone","otherNames":[]},{"type":"DRUG","name":"alfacalcidol","otherNames":[]}],"arms":[{"label":"1","type":"ACTIVE_COMPARATOR"},{"label":"2","type":"ACTIVE_COMPARATOR"}],"summary":"To determine the effect and safety of menatetrenone on treatment of postmenopausal osteoporosis comparing with alfacalcidol.","primaryOutcome":{"measure":"Bone Mineral Density BMD (Percentage) Change in Lumber Spine After 12 Months","timeFrame":"Baseline and 12 months","effectByArm":[{"arm":"Menatetrenone","deltaMin":1.22,"sd":null},{"arm":"Alfacalcidol","deltaMin":2.17,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.26"}]},"eligibility":{"minAge":"45 Years","sex":"FEMALE","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":12},"locations":{"siteCount":5,"countries":["China"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":8,"n":117},"commonTop":["Gastrointestinal disorders","Respiratory abnormalities","Others","Musculoskeletal system abnormalities","Abnormal Cardiovascular system"]}}